BioCentury | Feb 26, 2020

Bicycle’s bicyclic peptides attract Genentech as first corporate immuno-oncology partner

...ophthalmic diseases. ThromboGenics, now known as Oxurion N.V. (Euronext:OXUR), has the bicycle-based plasma kallikrein inhibitor THR-149...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Ophthalmic disease

...include testing the peptides in additional models of DME. Bicycle Therapeutics Ltd. and ThromboGenics have THR-149...
Items per page:
1 - 2 of 2